文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

床旁肺超声可预测COVID-19重症与死亡:一项前瞻性队列研究

Point-of-Care Lung Ultrasound Predicts Severe Disease and Death Due to COVID-19: A Prospective Cohort Study.
PubMed 文献 · Crit Care Explor · 2022-08-12
一句话结论住院COVID-19患者入院时平均肺超声评分(mLUSS)每升高1分,28天内需ICU级治疗风险aHR 3.61、死亡风险aHR 3.10,胸膜线异常者死亡aHR高达20.93。

该前瞻性队列研究在2020年4月至2021年9月于马里兰一家大型三级医疗中心纳入264例SARS-CoV-2 RT-PCR阳性的住院成人(中位年龄61岁,43.2%为女性),采用标准化12肺区方案行床旁肺超声并随访至出院及28天。中位mLUSS为1.0(IQR 0.5-1.3),入组后27例(10.0%)进展至需ICU级治疗、14例(5.3%)28天内死亡。校正年龄和性别后,mLUSS每增加1分与进展至ICU级治疗(aHR 3.61;95%CI 1.27-10.2)及28天死亡(aHR 3.10;95%CI 1.29-7.50)相关,胸膜线异常独立与进展至死亡相关(aHR 20.93;95%CI 3.33-131.30)。作者认为mLUSS≥1或胸膜线改变者后续需高流量氧疗或更高等级呼吸支持的可能性增加,床旁肺超声是评估COVID-19进展风险的有前景工具。

要点

  • 入组时mLUSS每增加1分,28天内进展至需ICU级治疗的风险aHR 3.61(95%CI 1.27-10.2),28天死亡风险aHR 3.10(95%CI 1.29-7.50)。
  • 胸膜线异常独立与28天内进展至死亡相关,aHR 20.93(95%CI 3.33-131.30)。
  • 264例住院COVID-19成人中,27例(10.0%)后续需ICU级治疗,14例(5.3%)28天内死亡。
  • 作者结论:mLUSS≥1或存在胸膜线改变的患者,后续需要高流量氧疗或更高等级呼吸支持的可能性增加。
  • 床旁肺超声采用标准化12肺区方案,mLUSS取值范围0-3,本研究队列中位mLUSS为1.0(IQR 0.5-1.3)。

适用人群与场景

  • 住院成人(≥18岁)且SARS-CoV-2逆转录聚合酶链反应阳性者。
  • 场景为马里兰一家大型三级医疗中心住院患者,超声于入组时完成。

诊断标准与关键阈值

  • 床旁肺超声采用标准化方案,包括12个肺区,评估肺与胸膜线伪影及异常,并计算各肺区平均肺超声评分(mLUSS),mLUSS取值范围0-3。
  • ICU级治疗定义为高流量氧疗、无创或有创机械通气。

红旗征与不能漏的情况

  • mLUSS≥1或胸膜线改变的患者,后续需要高流量氧疗或更高等级呼吸支持的可能性增加(作者结论)。

研究设计与关键结果

  • 研究类型:前瞻性队列研究;样本量264例;中位年龄61岁,女性114例(43.2%)。
  • 中位mLUSS为1.0(四分位距0.5-1.3);入组后27例(10.0%)需ICU级治疗,14例(5.3%)28天内死亡。
  • 校正年龄和性别后,入组时mLUSS每增加1分与进展至ICU级治疗相关(aHR 3.61;95%CI 1.27-10.2)。
  • 校正年龄和性别后,入组时mLUSS每增加1分与28天死亡相关(aHR 3.10;95%CI 1.29-7.50)。
  • 胸膜线异常独立与进展至死亡相关(aHR 20.93;95%CI 3.33-131.30)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,床旁肺超声是评估COVID-19进展风险的有前景工具。
  • 作者结论:mLUSS≥1或胸膜线改变的患者,后续需要高流量氧疗或更高等级呼吸支持的可能性增加。
  • 研究干预为标准化12肺区床旁肺超声评估,非治疗性干预。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: The clinical utility of point-of-care lung ultrasound (LUS) among hospitalized patients with COVID-19 is unclear.

DESIGN: Prospective cohort study.

SETTING: A large tertiary care center in Maryland, between April 2020 and September 2021.

PATIENTS: Hospitalized adults (≥ 18 yr old) with positive severe acute respiratory syndrome coronavirus 2 reverse transcriptase-polymerase chain reaction results.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: All patients were scanned using a standardized protocol including 12 lung zones and followed to determine clinical outcomes until hospital discharge and vital status at 28 days. Ultrasounds were independently reviewed for lung and pleural line artifacts and abnormalities, and the mean LUS Score (mLUSS) (ranging from 0 to 3) across lung zones was determined. The primary outcome was time to ICU-level care, defined as high-flow oxygen, noninvasive, or invasive mechanical ventilation, within 28 days of the initial ultrasound. Cox proportional hazards regression models adjusted for age and sex were fit for mLUSS and each ultrasound covariate. A total of 264 participants were enrolled in the study; the median age was 61 years and 114 participants (43.2%) were female. The median mLUSS was 1.0 (interquartile range, 0.5-1.3). Following enrollment, 27 participants (10.0%) went on to require ICU-level care, and 14 (5.3%) subsequently died by 28 days. Each increase in mLUSS at enrollment was associated with disease progression to ICU-level care (adjusted hazard ratio [aHR], 3.61; 95% CI, 1.27-10.2) and 28-day mortality (aHR, 3.10; 95% CI, 1.29-7.50). Pleural line abnormalities were independently associated with disease progression to death (aHR, 20.93; CI, 3.33-131.30).

CONCLUSIONS: Participants with a mLUSS greater than or equal to 1 or pleural line changes on LUS had an increased likelihood of subsequent requirement of high-flow oxygen or greater. LUS is a promising tool for assessing risk of COVID-19 progression at the bedside.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Blair PW, Siddharthan T, Liu G, et al. Point-of-Care Lung Ultrasound Predicts Severe Disease and Death Due to COVID-19: A Prospective Cohort Study. Crit Care Explor. 2022. PMID: 35982837. doi:10.1097/CCE.0000000000000732

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。